Biobot is a Singapore-based medical robotics company specializing in robotic prostate biopsy and treatment solutions. Its flagship product, the iSR'obot Mona Lisa system, provides urologists with robotic precision and enhanced visualization for percutaneous transperineal procedures. The technology is already in clinical use globally, with more than 50 Mona Lisa robots deployed and over 20,000 procedures completed. Biobot raised $24M in a Series B round led by Mr. Tony Tan, with participation from ZIG Ventures and new strategic investors. The company plans to use the proceeds to expand its presence worldwide and to further develop its digital surgery infrastructure. Biobot is dedicated to redefining the standard of care in urology through technological innovation.

Total raised

$24M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2024